Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christina Celmer

Physician Assistant Brick, NJ Physician Assistant

NPI 1841354230 CMS profile 10437137

1640 Route 88 Ste 201, Brick, NJ 08724

Open in the dashboard

General payments

$8,710

663 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Celmer of Brick, NJ is reported in the CMS Open Payments database as having received $8,710 across 663 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,891 128
2024 General $2,069 166
2023 General $1,726 126
2022 General $1,855 149
2021 General $1,170 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Celmer
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christina Celmer were reported at $1,891. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christina Celmer Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,170 $132 $37–$438 $132
2022 $1,855 $155 $48–$522 $149
2023 $1,726 $167 $52–$557 $160
2024 $2,069 $178 $55–$600 $164
2025 $1,891 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $1,598 143 payments
  2. Novartis Pharmaceuticals Corporation $841 104 payments
  3. Amgen Inc. $825 53 payments
  4. Janssen Pharmaceuticals, Inc $747 64 payments
  5. Pfizer Inc. $739 66 payments
  6. Novo Nordisk Inc $591 39 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $569 38 payments
  8. AstraZeneca Pharmaceuticals LP $568 29 payments
  9. Merck Sharp & Dohme Corporation $293 20 payments
  10. Abbott Laboratories $245 9 payments
  11. Other $1,694 98 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,675 661 payments
  2. Education $35 2 payments
Products named General payments · program years 2021–2025
  1. CAMZYOS $842 56 payments
  2. XARELTO $747 64 payments
  3. ELIQUIS Cardiovascular $730 83 payments
  4. Repatha $641 41 payments
  5. LEQVIO $519 71 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $431 30 payments
  7. Wegovy $395 27 payments
  8. FARXIGA $356 15 payments
  9. VYNDAQEL $344 38 payments
  10. VERQUVO $326 22 payments
  11. Other $4,666 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

663 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record